Neuroprotective properties of GLP-1: theoretical and practical applications

Adiposity, Type 2 Diabetes, and Alzheimer's Disease

(2017) José A. Luchsinger et al.   JOURNAL OF ALZHEIMERS DISEASE

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

(2017) Yazhou Li et al.   JOURNAL OF ALZHEIMERS DISEASE

Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist

(2010) Elena-Dana Baraboi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model

(2010) Paola Luciani et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor Expression

(2010) Marion Cornu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Why Pleiotropic Interventions are Needed for Alzheimer's Disease

(2010) Sally A. Frautschy et al.   MOLECULAR NEUROBIOLOGY

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides

(2010) Niels Vrang et al.   PROGRESS IN NEUROBIOLOGY

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

(2009) Le Thi Kim Chung et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

(2009) L. BLONDE   CLEVELAND CLINIC JOURNAL OF MEDICINE

A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism

(2009) Remy Burcelin et al.   CURRENT OPINION IN PHARMACOLOGY

Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice

(2009) J. F. Aitken et al.   DIABETES

Glucagon-Like Peptide-1 Protects  -Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop

(2009) M. Cornu et al.   DIABETES

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Minireview: Finding the Sweet Spot: PeripheralVersusCentral Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis

(2009) Diana L. Williams   ENDOCRINOLOGY

Incretin Therapies: Effects Beyond Glycemic Control

(2009) Sunder Mudaliar et al.   European Journal of Internal Medicine

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice

(2009) Michele D’Amico et al.   EXPERIMENTAL GERONTOLOGY

Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons

(2009) Denise D. Belsham et al.   FASEB JOURNAL

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides

(2009) Rania Abu-Hamdah et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas

(2009) Emanuel Christ et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

(2009) Sehee Kim et al.   JOURNAL OF ENDOCRINOLOGY

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat

(2009) v. bucinskaite et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

(2009) Kristopher C. Dozier et al.   PEPTIDES

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pancreatic β-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes

(2009) Meena Asmar et al.   REGULATORY PEPTIDES

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Exendin-4 Protects  -Cells From Interleukin-1 -Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway

(2008) M. Ferdaoussi et al.   DIABETES

Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

(2008) C. Cabou et al.   DIABETES

Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing

(2008) C. Knauf et al.   DIABETES

Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease

(2008) B. Martin et al.   DIABETES

Pancreatic α-cell dysfunction in diabetes

(2008) R. Burcelin et al.   DIABETES & METABOLISM

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

(2008) Victor A. Gault et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease

(2008) José Alejandro Luchsinger   EUROPEAN JOURNAL OF PHARMACOLOGY

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Parkinson's disease: clinical features and diagnosis

(2008) J Jankovic   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin

(2008) C.G. Jolivalt et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology

(2008) M. S. Beeri et al.   NEUROLOGY

Inflammation as a causative factor in the aetiology of Parkinson's disease

(2007) P S Whitton   BRITISH JOURNAL OF PHARMACOLOGY

Amyloid beta oligomers induce impairment of neuronal insulin receptors

(2007) Wei-Qin Zhao et al.   FASEB JOURNAL

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES